Delving into the Latest Updates on XH-5102 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

JRF105, XH 5102, XH5102

Target

JAK2

Mechanism

JAK2 inhibitors(Tyrosine-protein kinase JAK2 inhibitors)

Therapeutic Areas

NeoplasmsHemic and Lymphatic DiseasesOther Diseases+ [2]

Active Indication

Bone Marrow NeoplasmsMyelofibrosisPhiladelphia chromosome positive chronic myelogenous leukemia+ [3]

Inactive Indication-

Originator Organization

Shanghai Xunhe Pharmaceutical Technology Co., Ltd

Active Organization

Shanghai Xunhe Pharmaceutical Technology Co., Ltd

Chengdu Jinruijiye Biotechnology Co., Ltd

Inactive Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

主要研究目的观察XH-5102片单次及多次口服给药在骨髓增殖性肿瘤患者中的安全性和耐受性，确定XH-5102片单次及多次口服给药在骨髓增殖性肿瘤患者中的最大耐受剂量（MTD）和/或后期临床研究推荐剂量。次要研究目的 1) 观察XH-5102片在骨髓增殖性肿瘤患者中的药代动力学特征； 2) 初步评价XH-5102片治疗骨髓增殖性肿瘤的初步有效性。

[Translation]

Main study objectives To observe the safety and tolerability of single and multiple oral administration of XH-5102 tablets in patients with myeloproliferative neoplasms, and to determine the maximum tolerated dose (MTD) and/or recommended dose for later clinical studies of single and multiple oral administration of XH-5102 tablets in patients with myeloproliferative neoplasms. Secondary study objectives 1) To observe the pharmacokinetic characteristics of XH-5102 tablets in patients with myeloproliferative neoplasms; 2) To preliminarily evaluate the preliminary effectiveness of XH-5102 tablets in the treatment of myeloproliferative neoplasms.

Start Date29 Mar 2023

Sponsor / Collaborator

Shanghai Xunhe Pharmaceutical Technology Co., Ltd

ChiCTR2300069803 / SuspendedPhase 1/2IIT

A phase I/II study to evaluate the safety, tolerance, pharmacokinetic characteristics and preliminary efficacy of XH-5102 tablets administered orally in patients with myeloproliferative tumors

Start Date27 Mar 2023

Sponsor / Collaborator

Shanghai First People's Hospital

100 Clinical Results associated with XH-5102

Login to view more data

100 Translational Medicine associated with XH-5102

Login to view more data

100 Patents (Medical) associated with XH-5102

Login to view more data

100 Deals associated with XH-5102

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bone Marrow Neoplasms	Phase 2	CN	Shanghai Xunhe Pharmaceutical Technology Co., Ltd	16 Jan 2023
Myelofibrosis	Phase 1	CN	Shanghai Xunhe Pharmaceutical Technology Co., Ltd	02 Aug 2022
Philadelphia chromosome positive chronic myelogenous leukemia	Phase 1	CN	Shanghai Xunhe Pharmaceutical Technology Co., Ltd	02 Aug 2022
Thrombocythemia, Essential	Phase 1	CN	Shanghai Xunhe Pharmaceutical Technology Co., Ltd	02 Aug 2022
Chronic Kidney Diseases	Preclinical	CN	Chengdu Jinruijiye Biotechnology Co., Ltd	26 Apr 2023
Diabetic Nephropathies	Preclinical	CN	Chengdu Jinruijiye Biotechnology Co., Ltd	26 Apr 2023